Dose Insider / Glossary / CagriSema

CagriSemaWhat it is and what the REDEFINE trials showed

Updated November 20, 2026 路 4 min read 路 REDEFINE 1 and 2 (NEJM 2025), phase 1b (Lancet 2021), DailyMed

CagriSema is an experimental combination from Novo Nordisk of two medicines given together once a week: cagrilintide, a long-acting copy of the hormone amylin, and semaglutide, the GLP-1 medicine in Wegovy, each at 2.4 mg.

20.4%Without diabetes, CagriSema, weight lost by week 68
Weight lost by week 68REDEFINE trials, % of starting weightWITHOUT DIABETESCagriSema20.4%Placebo3.0%WITH TYPE 2 DIABETESCagriSema13.7%Placebo3.4%Weight lost by week 68REDEFINE trials, % of starting weightWITHOUT DIABETESCagriSema20.4%Placebo3.0%WITH TYPE 2 DIABETESCagriSema13.7%Placebo3.4%

Both doses 2.4 mg, once a week; funded by Novo Nordisk.

On this page

In the 68-week REDEFINE 1 trial, adults without diabetes lost 20.4% of their weight on it, against 3.0% on placebo.1 We found no label for it on DailyMed, the U.S. database of drug labels, on November 20, 2026.2

Why combine the two

Amylin is released with insulin after meals and helps end a meal; it slows stomach emptying, holds back glucagon and acts on appetite in the brain.3 GLP-1 does several of the same things through a different receptor. The idea behind CagriSema is that acting on both pathways lowers weight more than either alone. Cagrilintide on its own lowered weight by up to 10.8% in a 26-week trial, against 3.0% on placebo.4

The two parts last a similar time in the body. In an early trial, cagrilintide had a half-life of 159 to 195 hours and semaglutide 2.4 mg 145 to 165 hours, both around a week, and adding cagrilintide did not change how semaglutide was absorbed or cleared.5

The first combined trial

The 2021 phase 1b trial gave 96 adults semaglutide 2.4 mg together with rising doses of cagrilintide or placebo. At week 20, weight fell by 17.1% with cagrilintide 2.4 mg added, against 9.8% with semaglutide and placebo.5 That gap, in a small and short trial, is what led to the large phase 3 program.

REDEFINE 1, without diabetes

REDEFINE 1 enrolled 3,417 adults without diabetes with a body mass index of 30 or more, or 27 or more with a weight-related complication. They were assigned to CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone or placebo, with lifestyle advice for all, for 68 weeks. Weight fell by 20.4% on CagriSema against 3.0% on placebo, and more people on CagriSema reached losses of 5%, 20%, 25% and 30%.1

REDEFINE 2, with type 2 diabetes

REDEFINE 2 enrolled 1,206 adults with type 2 diabetes, an HbA1c of 7% to 10% and a body mass index of 27 or more. Over 68 weeks weight fell by 13.7% on CagriSema against 3.4% on placebo, and an HbA1c of 6.5% or less was reached by 73.5% against 15.9%.6 As with other GLP-1 medicines, weight loss was smaller in people with diabetes than without.

Side effects

Stomach and gut events, including nausea, vomiting, diarrhea, constipation and abdominal pain, were reported by 79.6% on CagriSema against 39.9% on placebo in REDEFINE 1, and by 72.5% against 34.4% in REDEFINE 2. Both reports describe most of them as short-lived and mild to moderate.1,6 Our page on nausea on a GLP-1 covers what helps.

What is still open

REDEFINE 1 also had groups on semaglutide alone and cagrilintide alone, but the published summary we read gives only the comparison with placebo. So this page cannot say how much of the 20.4% each part contributed. The one direct comparison of semaglutide with and without cagrilintide in our sources is the phase 1b trial, which lasted 20 weeks and enrolled 96 adults.1,5 Those are the numbers to watch when the full results of the semaglutide-only group are compared side by side.

Next to the approved medicines

In its own label trial, Wegovy 2.4 mg alone lowered weight by 14.9% over 68 weeks, and Zepbound 15 mg by 20.9% over 72 weeks.7 CagriSema's 20.4% sits close to the Zepbound figure, but the trials differ in people and design and were not run against each other. All trials of CagriSema described here were funded by Novo Nordisk.1,5,6

Sources

  1. Garvey WT, Bl眉her M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025;393:635-647. Funded by Novo Nordisk. doi:10.1056/NEJMoa2502081
  2. DailyMed, U.S. National Library of Medicine. Search for "cagrilintide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  3. SYMLINPEN (pramlintide acetate) injection prescribing information. AstraZeneca; DailyMed, version published August 20, 2024; section 12.1. dailymed.nlm.nih.gov
  4. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet 2021;398:2160-2172. Funded by Novo Nordisk. doi:10.1016/S0140-6736(21)01751-7
  5. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021;397:1736-1748. doi:10.1016/S0140-6736(21)00845-X
  6. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med 2025;393:648-659. Funded by Novo Nordisk. doi:10.1056/NEJMoa2502082
  7. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, section 14; and ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, section 14. U.S. Food and Drug Administration. accessdata.fda.gov

Related analyses

Log any GLP-1 medicine you take and see your doses, weight and symptoms together.

Open Dose Insider